JPH10147523A - Medicine, and food and feed composition, having improving activity of blood fluidity - Google Patents
Medicine, and food and feed composition, having improving activity of blood fluidityInfo
- Publication number
- JPH10147523A JPH10147523A JP8322163A JP32216396A JPH10147523A JP H10147523 A JPH10147523 A JP H10147523A JP 8322163 A JP8322163 A JP 8322163A JP 32216396 A JP32216396 A JP 32216396A JP H10147523 A JPH10147523 A JP H10147523A
- Authority
- JP
- Japan
- Prior art keywords
- linolenic acid
- blood
- fluidity
- food
- blood fluidity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、医療分野において
有用な血液流動性改善作用を有する医薬、並びに食品分
野，飼料分野（ペットフード分野など）等において有用
な血液流動性改善作用を有する食品・飼料組成物に関す
る。The present invention relates to a medicament having a blood fluidity improving action useful in the medical field, and a food and a food having a blood fluidity improving action useful in the food field, feed field (pet food field, etc.). It relates to a feed composition.
【０００２】[0002]
【従来の技術】高級脂肪酸の一つであるγ−リノレン酸
は、健康食品やペットフードなどに広く用いられてい
る。このようにγ−リノレン酸については、栄養学的な
観点からの健康増進効果が従来から認められている。2. Description of the Related Art Gamma-linolenic acid, one of higher fatty acids, is widely used in health foods and pet foods. As described above, γ-linolenic acid has been conventionally recognized as having a health-promoting effect from a nutritional point of view.
【０００３】しかしながら、γ−リノレン酸について、
医薬的な観点からは、未だ充分な検討がなされていない
のが実情である。However, regarding γ-linolenic acid,
From the medical point of view, the fact is that sufficient studies have not yet been made.
【０００４】このような状況下、本出願人は、γ−リノ
レン酸等を含有する人工透析患者の皮膚そう痒症治療組
成物及び副甲状腺機能亢進症治療組成物を既に提案して
いる（特開平７−２３３０６２号公報）。この発明によ
れば、γ−リノレン酸等を含有する組成物を人工透析患
者に服用させることにより、かゆみ、副甲状腺ホルモン
を低下させ得ることが可能となった。Under such circumstances, the present applicant has already proposed a composition for treating pruritus cutaneous and hyperparathyroidism in dialysis patients, which contains γ-linolenic acid or the like (Japanese Patent Application Laid-Open No. H11-157,086). JP-A-7-233062). According to the present invention, itching and parathyroid hormone can be reduced by taking a composition containing γ-linolenic acid or the like to an dialysis patient.
【０００５】[0005]
【発明が解決しようとする課題】本発明者らは、このよ
うなγ−リノレン酸について、さらなる用途開発を行な
うべく、鋭意研究を重ねた。その結果、本発明者らは、
γ−リノレン酸とビタミンＥとを人工透析患者に服用さ
せたところ、血液、特に白血球の流動性が著しく改善さ
れていることを初めて知見し、この知見に基づいて本発
明を完成するに到った。DISCLOSURE OF THE INVENTION The present inventors have intensively studied such .gamma.-linolenic acid in order to further develop uses thereof. As a result, we have:
When gamma-linolenic acid and vitamin E were administered to dialysis patients, it was found for the first time that the fluidity of blood, particularly leukocytes, was significantly improved, and the present invention was completed based on this finding. Was.
【０００６】すなわち本発明は、血液の流動性改善作
用、特に優れた白血球の流動性改善作用を有する、安全
性に優れた医薬、並びに食品・飼料組成物を提供するこ
とを目的とするものである。血液の流動性が向上するの
は、白血球、赤血球の流動性が向上するためである。That is, an object of the present invention is to provide a highly safe drug, food and feed composition having a blood fluidity improving effect, particularly an excellent leukocyte fluidity improving effect. is there. The reason why the fluidity of blood is improved is that the fluidity of white blood cells and red blood cells is improved.
【０００７】なお、γ−リノレン酸を人工透析患者に服
用させ、血液の流動性を調べたとの報告は勿論のこと、
血液の流動性、とりわけ白血球の流動性が向上する旨の
報告は、これまで全くなされていない。[0007] In addition to reports that γ-linolenic acid was taken by dialysis patients and the fluidity of blood was examined,
There has been no report to date that the fluidity of blood, especially the fluidity of leukocytes, is improved.
【０００８】寧ろ、それとは反対に、γ−リノレン酸
（月見草油）をアトピー症の子供に服用させたが、赤血
球の流動性は変化しなかったとの報告がある（ Biagi P
Let al. Drugs Under Experimental and Clinical Res
earch 20(2),1994; p77-84) 。On the contrary, it has been reported that γ-linolenic acid (evening primrose oil) was given to children with atopic disease but the fluidity of red blood cells did not change (Biagi P.
Let al. Drugs Under Experimental and Clinical Res
earch 20 (2), 1994; p77-84).
【０００９】[0009]
【課題を解決するための手段】請求項１記載の本発明
は、γ−リノレン酸単独又はγ−リノレン酸と脂溶性抗
酸化剤とを有効成分とする血液流動性改善作用を有する
医薬を提供するものである。The present invention according to claim 1 provides a medicine having an effect of improving blood fluidity, comprising γ-linolenic acid alone or γ-linolenic acid and a fat-soluble antioxidant as active ingredients. Is what you do.
【００１０】また、請求項５記載の本発明は、γ−リノ
レン酸単独又はγ−リノレン酸と脂溶性抗酸化剤とを含
有することを特徴とする血液流動性改善作用を有する食
品・飼料組成物を提供するものである。A fifth aspect of the present invention provides a food or feed composition having an effect of improving blood fluidity, which comprises γ-linolenic acid alone or γ-linolenic acid and a fat-soluble antioxidant. It provides things.
【００１１】[0011]
【発明の実施の形態】以下、本発明について説明する。
本発明で用いるγ−リノレン酸とは、狭義のγ−リノレ
ン酸、ジホモ−γ−リノレン酸及びこれらの誘導体を含
む広義のものである。なお、本明細書では、特に狭義の
γ−リノレン酸と指称しない限り、広義のγ−リノレン
酸を指す。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below.
The term γ-linolenic acid used in the present invention has a broad meaning including γ-linolenic acid, dihomo-γ-linolenic acid and derivatives thereof in a narrow sense. In the present specification, unless otherwise specifically referred to as γ-linolenic acid in a narrow sense, it refers to γ-linolenic acid in a broad sense.
【００１２】本発明の血液流動性改善作用を有する医
薬、或いは血液流動性改善作用を有する食品・飼料組成
物は、このようなγ−リノレン酸単独の他、γ−リノレ
ン酸に脂溶性抗酸化剤を加えたものを有効成分としたり
（請求項１記載の血液流動性改善作用を有する医薬）、
或いは含有したり（請求項２記載の血液流動性改善作用
を有する食品・飼料組成物）するものである。ここで、
血液流動性改善作用とは、例えば人工透析患者のよう
に、以前より低下している血液流動性を元に戻す（健常
時に戻す）作用と、通常の血液流動性をさらに向上させ
る作用との両方を含む概念である。The medicament having a blood fluidity improving effect or the food / feed composition having a blood fluidity improving effect according to the present invention is not only such γ-linolenic acid alone but also a fat-soluble antioxidant to γ-linolenic acid. A drug having an action of improving blood fluidity according to claim 1 or
Alternatively, it is contained (a food / feed composition having a blood fluidity improving effect according to claim 2). here,
The blood fluidity improving action is both an action of restoring blood fluidity that has been reduced from the previous time (returning to a healthy state), as in an dialysis patient, and an action of further improving normal blood fluidity. It is a concept including
【００１３】なお、請求項１記載の本発明における「医
薬」とは、人の病気の診断，治療，処置又は予防のため
使用される物であることは言うまでもない。具体的に
は、請求項１記載の本発明において、「医薬」とは、薬
事法上の「医薬品」を指す。It is needless to say that the "medicine" in the present invention described in claim 1 is used for diagnosis, treatment, treatment or prevention of human diseases. Specifically, in the present invention described in claim 1, the “medicine” refers to a “medicine” in the Pharmaceutical Affairs Law.
【００１４】上記γ−リノレン酸は、ムコール ( Mucor
)属、モルティエレラ ( Mortierella )属、リゾプス
( Rizopus )属等の糸状菌、或いは月見草，ボラージ等
の植物、さらにはスピルリナ等の藻類等に含まれる油脂
から得られるが、これらをそのまま用いても良いし、こ
れらからの抽出物や、さらに精製したものを用いても良
い。また、γ−リノレン酸は、化学合成によって得るこ
ともでき、市販されているものを使用しても良い。な
お、γ−リノレン酸は高級脂肪酸であって、元来、ヒト
母乳に含まれている生体成分であり、また食用にも用い
られており、安全性には特に問題はない。また、ジホモ
−γ−リノレン酸についても、微生物由来のものや、化
学合成品があるが、起源については特に制限はない。The above-mentioned γ-linolenic acid is obtained from Mucor
Genus, Mortierella , Rhizopus
It is obtained from filamentous fungi of the genus ( Rizopus ) or plants such as evening primrose and borage, and oils and fats contained in algae such as spirulina. A purified product may be used. Further, γ-linolenic acid can be obtained by chemical synthesis, and a commercially available product may be used. It should be noted that γ-linolenic acid is a higher fatty acid, is a biological component originally contained in human breast milk, and is also used for edible use, and there is no particular problem in safety. Also, dihomo-γ-linolenic acid may be derived from microorganisms or chemically synthesized, but the origin is not particularly limited.
【００１５】狭義のγ−リノレン酸或いはジホモ−γ−
リノレン酸の誘導体としては、これらと、各種アルコー
ル類との反応により得られるエステル、例えばエチルエ
ステル，グリセロールエステル、リン脂質等、或いは無
機，有機の塩基とを、等モル比で作用して得られる塩、
例えばナトリウム塩，カリウム塩等が挙げられる。Γ-linolenic acid or dihomo-γ- in a narrow sense
The derivatives of linolenic acid can be obtained by reacting them with an ester obtained by reaction with various alcohols, for example, ethyl ester, glycerol ester, phospholipid, etc., or an inorganic or organic base in an equimolar ratio. salt,
For example, sodium salt, potassium salt and the like can be mentioned.
【００１６】本発明の血液流動性向上作用を有する医薬
或いは血液流動性向上作用を有する食品・飼料組成物に
おいては、上記の如きγ−リノレン酸を単独で用いても
良いが、γ−リノレン酸に脂溶性抗酸化剤を加えたもの
を用いることもできる。ここで脂溶性抗酸化剤として
は、ビタミンＥ、補酵素Ｑ、アスコルビルパルミテー
ト、アスコルビルステアレート、β−カロチン、リコペ
ン等を挙げることができ、これらの中でも、抗酸化作用
の他に、流動性改善作用をも有すると認められる点か
ら、特にビタミンＥ、補酵素Ｑを用いることが好まし
い。In the medicament having a blood fluidity improving effect or the food / feed composition having a blood fluidity improving effect of the present invention, γ-linolenic acid as described above may be used alone. It is also possible to use a mixture obtained by adding a fat-soluble antioxidant to the mixture. Here, as the fat-soluble antioxidant, vitamin E, coenzyme Q, ascorbyl palmitate, ascorbyl stearate, β-carotene, lycopene and the like can be mentioned. It is particularly preferable to use vitamin E and coenzyme Q from the viewpoint of having an improving effect.
【００１７】この場合、脂溶性抗酸化剤は、γ−リノレ
ン酸に対して、通常は、５０重量％以下、好ましくは１
〜５０重量％の割合、より好ましくは２〜３０重量％の
割合で用いられる。In this case, the fat-soluble antioxidant is usually 50% by weight or less, preferably 1% by weight, based on γ-linolenic acid.
It is used in a proportion of ５０50% by weight, more preferably in a proportion of 2 to 30% by weight.
【００１８】本発明の血液流動性改善作用を有する医薬
或いは食品・飼料組成物は、基本的には上記成分よりな
るものであるが、必要に応じてα−リノレン酸、エイコ
サペンタエン酸やドコサヘキサエン酸などのω３系の不
飽和脂肪酸、ミリストオレイン酸などのω５系の不飽和
脂肪酸、パルミトオレイン酸などのω７系の不飽和脂肪
酸、オレイン酸，エルシン酸などのω９系の不飽和脂肪
酸、ラウリン酸，ミリスチン酸などの飽和脂肪酸を任意
の割合で添加しても良い。The pharmaceutical or food / feed composition having an effect of improving blood fluidity according to the present invention is basically composed of the above-mentioned components. If necessary, α-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid are used. Ω3 unsaturated fatty acids such as myristooleic acid, ω7 unsaturated fatty acids such as palmitooleic acid, ω9 unsaturated fatty acids such as oleic acid and erucic acid, and laurin Saturated fatty acids such as acid and myristic acid may be added at an arbitrary ratio.
【００１９】なお、食品組成物とする場合には、添加剤
としては、食品衛生法上、許容されているものを使用す
る必要があることは言うまでもない。In the case of a food composition, it goes without saying that it is necessary to use additives permitted under the Food Sanitation Law.
【００２０】本発明の血液流動性改善作用を有する医薬
の剤型は特に限定されないが、狭義のγ−リノレン酸、
ジホモ−γ−リノレン酸及びこれらの誘導体から選ばれ
る１種又は２種以上のもの、或いは上記した糸状菌類や
植物等の油脂から得られる抽出物を、一般に製剤上許容
される無害の１種又は２種以上のベヒクル、担体、賦形
剤、統合剤、防腐剤、安定剤、香味剤等と共に混和し
て、錠剤、顆粒剤、カプセル剤、水剤等の内服剤；無菌
溶液剤、懸濁液剤等の注射薬；輸液としたものを用いる
ことができる。これらは、従来公知の技術を用いて製造
することができる。The dosage form of the medicament having an action of improving blood fluidity of the present invention is not particularly limited, but γ-linolenic acid in a narrow sense,
One or two or more selected from dihomo-γ-linolenic acid and derivatives thereof, or an extract obtained from oils and fats of the above-described filamentous fungi and plants, is generally one of harmless and pharmaceutically acceptable or Mix with 2 or more types of vehicles, carriers, excipients, integrating agents, preservatives, stabilizers, flavoring agents, etc., and take internal medicines such as tablets, granules, capsules, solutions, etc .; sterile solutions, suspensions Injectables such as liquids; infusions can be used. These can be manufactured using a conventionally known technique.
【００２１】例えば、狭義のγ−リノレン酸、ジホモ−
γ−リノレン酸及びこれらの誘導体から選ばれる１種又
は２種以上のものと、コーンスターチ，ゼラチン等の結
合剤、微晶性セルロース等の賦形剤、馬鈴薯デンプン，
アルギン酸ナトリウム等の膨化剤、乳糖，ショ糖等の甘
味剤等を配剤して、錠剤、顆粒剤などとすることができ
る。また、常法に従い、γ−リノレン酸と他の油脂類と
の混合物を軟質ゼラチンカプセル，硬質ゼラチンカプセ
ル等に充填して、カプセル剤を調製することができる。
さらに、常法により、シクロデキストリンとγ−リノレ
ン酸とのシクロデキストリン包接物とすることもでき
る。For example, γ-linolenic acid, dihomo-
one or more selected from γ-linolenic acid and derivatives thereof, a binder such as corn starch and gelatin, an excipient such as microcrystalline cellulose, potato starch,
Tablets, granules and the like can be prepared by dispersing a leavening agent such as sodium alginate and sweeteners such as lactose and sucrose. In addition, a capsule can be prepared by filling a mixture of γ-linolenic acid and other fats and oils into a soft gelatin capsule, a hard gelatin capsule, or the like according to a conventional method.
Furthermore, a cyclodextrin clathrate of cyclodextrin and γ-linolenic acid can be obtained by a conventional method.
【００２２】なお、食品・飼料組成物とする場合には、
上記成分を単に混合すれば良いが、さらにこのような組
成物を、上記と同様にして製剤化し、これを摂取しても
良いし、さらにこれらのものを食品や飼料と混ぜ合わせ
ても良い。特に食品組成物とする場合には、一般の食
品、例えばウエハース，ゼリー，ドレッシング，マーガ
リンなど各種食品中に混ぜ合わせることもできる。混ぜ
合わせ得る食品の種類は特に制限はない。In the case of a food / feed composition,
The above components may be simply mixed, but such a composition may be formulated in the same manner as described above and ingested, or these may be mixed with food or feed. In particular, in the case of a food composition, it can be mixed with general foods, for example, various foods such as wafers, jellies, dressings, and margarine. There are no particular restrictions on the types of foods that can be mixed.
【００２３】投与（服用）量に関しては、狭義のγ−リ
ノレン酸、ジホモ−γ−リノレン酸及びこれらの誘導体
の量は、患者・摂取者の年齢、病歴、疾患の種類、症状
等に応じて適宜設定すれば良い。通常は、γ−リノレン
酸として、５〜５０００ｍｇ／日の範囲、好ましくは１
０〜２０００ｍｇ／日の範囲であり、より好ましくは３
０〜１０００ｍｇ／日の範囲で用いれば良い。投与量が
少な過ぎると、充分な血液流動性向上作用を奏すること
ができない。投与（服用）は、一般的には毎日行なう
が、隔日であっても良く、患者・摂取者の年齢、病歴、
疾患の種類、症状等に応じて適宜設定すれば良い。With respect to the amount of administration (dose), the amount of γ-linolenic acid, dihomo-γ-linolenic acid and derivatives thereof in a narrow sense depends on the age, medical history, type of disease, symptom, etc. of the patient / ingestor. What is necessary is just to set suitably. Usually, γ-linolenic acid is in the range of 5 to 5000 mg / day, preferably 1 to 5000 mg / day.
0 to 2000 mg / day, more preferably 3 mg / day.
It may be used in the range of 0 to 1000 mg / day. If the dose is too small, a sufficient blood fluidity improving effect cannot be achieved. The administration (dose) is generally performed daily, but may be performed every other day.
What is necessary is just to set suitably according to the kind of a disease, a symptom, etc.
【００２４】具体的には、例えば、製品はゼラチンカプ
セルに充填したカプセル剤の形で投与され、カプセル剤
はγ−リノレン酸を５０ｍｇ含み、血液流動性の向上が
望まれる患者に１日当たり１〜１０錠程度の服用量で投
与される。Specifically, for example, the product is administered in the form of a capsule filled in a gelatin capsule, and the capsule contains 50 mg of γ-linolenic acid, and is preferably administered to a patient whose blood fluidity is desired to be increased by 1 to 1 per day. It is administered at a dose of about 10 tablets.
【００２５】請求項１記載の本発明の血液流動性改善作
用を有する医薬は、安全性に優れ、ヒトの血液流動性改
善剤として、特に人工透析患者の血液流動性改善剤とし
て有用である。とりわけ白血球の流動性改善剤として、
人工透析患者や糖尿病患者、さらにはこれらの予備軍的
なものに対する予防薬として有用である。The medicament of the present invention having a blood fluidity improving effect according to the present invention is excellent in safety and useful as a human blood fluidity improving agent, particularly as a blood fluidity improving agent for artificial dialysis patients. Especially as a leukocyte fluidity improver,
It is useful as a prophylactic for dialysis patients and diabetics, as well as these reserves.
【００２６】また、請求項２記載の本発明の血液流動性
改善作用を有する食品・飼料組成物は、安全性に優れて
おり、しかもヒトの食する食品のみならず、飼料とし
て、特にペットフードなどへ配合することにより、動物
の血液流動性の改善に有効に用いることができる。The food and feed composition of the present invention having a blood fluidity improving effect according to the present invention is excellent in safety, and is used not only for foods eaten by humans but also as feeds, especially pet foods. Incorporation into such as can be used effectively for improving blood fluidity of animals.
【００２７】[0027]
【実施例】以下、本発明を実施例により詳しく説明す
る。The present invention will be described below in more detail with reference to examples.
【００２８】製造例１（カプセル剤の製造） γ−リノレン酸を約２２重量％含有する油脂２３５重量
部と、ビタミンＥ（ミックス−トコフェノール）６５重
量部とを通常の方法で混合し、ゼラチンカプセル（富士
カプセル（株）製、フットボール型Ｎｏ．５）に充填し
て、１カプセル中にγ−リノレン酸を５０ｍｇ含むカプ
セルを製造した。Production Example 1 (Production of Capsules) 235 parts by weight of an oil or fat containing about 22% by weight of γ-linolenic acid and 65 parts by weight of vitamin E (mix-tocophenol) were mixed by a usual method, and gelatin was mixed. The capsule was filled into a capsule (Fuji Capsule Co., Ltd., football type No. 5) to produce a capsule containing 50 mg of γ-linolenic acid in one capsule.
【００２９】なお、上記γ−リノレン酸を含有する油脂
は、特開昭６３−２８３５８９号公報に記載の方法によ
り抽出したものを用いた。すなわち、ムコール・シロシ
ネロイデス（Mucor circinelloides ) ＨＵＴ（ＦＥＲ
Ｍ Ｐ−９３５９）の培養菌体から、ｎ−ヘキサン抽出
法により抽出することにより、γ−リノレン酸を含有す
る油脂を得た。As the fat or oil containing γ-linolenic acid, the one extracted by the method described in JP-A-63-283589 was used. In other words, Mucor Shiroshineroidesu (Muco r circinelloides) HUT (FER
(MP-9359) was extracted by the n-hexane extraction method to obtain an oil or fat containing γ-linolenic acid.
【００３０】実施例１（臨床試験） 製造例１で得られたカプセル剤を、人工透析患者５名
に、１日６カプセルの割合で（すなわち、γ−リノレン
酸として１日当たり３００ｍｇの割合で）２ヶ月間服用
させた。服用前、２週間後、４週間後のそれぞれ透析前
にヘパリン採血し、これを遠心分離により血球と血漿と
に分離した。赤血球に関する測定においては、ヘマトク
リット１２％になるように自己血漿で希釈した。白血球
に関しては、白血球数１２００個／ｍｍ3 になるよう
に、自己血漿で希釈した。Example 1 (Clinical Test) The capsules obtained in Production Example 1 were administered to 5 patients on artificial dialysis at a rate of 6 capsules per day (that is, at a rate of 300 mg per day as γ-linolenic acid). Take for 2 months. Heparin blood was collected before administration, 2 weeks and 4 weeks before dialysis, and separated into blood cells and plasma by centrifugation. For measurements on erythrocytes, the hematocrit was diluted with autologous plasma to 12%. The leukocytes were diluted with autologous plasma so that the number of leukocytes was 1200 / mm 3 .
【００３１】これらの希釈サンプルを、菊地の開発した
装置（「薬理と臨床」第６巻、第８号、１９９６年８
月）に導入し、一定の圧力で引き、サンプル５００ＵＬ
の全量が通過するのに必要な時間を測定した。なお、白
血球の測定には、径６μｍ、長さ１００μｍのマイクロ
チャンネルを用い、赤血球の測定には、径６μｍ、長さ
２０μｍのマイクロチャンネルを用いた。測定結果を表
１、表２にまとめた。Using these diluted samples, a device developed by Kikuchi ("Pharmacology and Clinical Practice", Vol. 6, No. 8, August 1996)
Month), pull at a constant pressure, and sample 500UL
The time required for the entire amount of to pass was measured. In addition, a microchannel having a diameter of 6 μm and a length of 100 μm was used for measurement of white blood cells, and a microchannel having a diameter of 6 μm and length of 20 μm was used for measurement of red blood cells. The measurement results are summarized in Tables 1 and 2.
【００３２】[0032]
【表１】 [Table 1]
【００３３】[0033]
【表２】 [Table 2]
【００３４】表１、表２から明らかなように、赤血球、
白血球共に、通過時間がγ−リノレン酸の服用により短
くなり、特に白血球については４週間後には著しく短く
なった。このことより、本発明の組成物の服用により、
赤血球、白血球の流動性が改善しており、従って血液の
流動性が改善していることが示された。As apparent from Tables 1 and 2, erythrocytes,
For both leukocytes, the transit time was shortened by taking γ-linolenic acid, and for leukocytes in particular, was significantly shortened after 4 weeks. From this, by taking the composition of the present invention,
It was shown that the fluidity of red blood cells and white blood cells was improved, and thus the fluidity of blood was improved.
【００３５】なお、服用開始前後には特別な治療などは
行なわれず、また、定期的に行なわれている臨床検査値
にも、特に異常は認められず、安全性にも問題がないこ
とが分かった。It should be noted that no special treatment was performed before and after the start of the administration, and no abnormalities were observed in the regularly performed clinical test values, and there was no problem in safety. Was.
【００３６】実施例２（急性毒性試験） γ−リノレン酸を約２５重量％含有する油脂について、
次のようにして急性毒性試験（単回投与毒性試験）を行
なった。すなわち、ＳＤ系ラット雌雄各５匹を用い、γ
−リノレン酸を約２５重量％含有する油脂を２ｇ／ｋｇ
単回投与したところ、一般状態、体重、剖検結果に異常
は認められず、雌雄共に脂肪例も見られなかった。単回
投与における半数致死量（ＬＤ50値）は、２ｇ／ｋｇ以
上で、安全性は高いと判断された。Example 2 (Acute Toxicity Test) For fats and oils containing about 25% by weight of γ-linolenic acid,
An acute toxicity test (single dose toxicity test) was performed as follows. That is, using 5 male and 5 female SD rats,
2 g / kg of fat or oil containing about 25% by weight of linolenic acid
After a single administration, no abnormalities were observed in the general condition, body weight, and autopsy results, and no fat cases were observed in both sexes. The half-lethal dose (LD 50 value) in a single administration was 2 g / kg or more, and the safety was judged to be high.
【００３７】[0037]
【発明の効果】請求項１記載の本発明の血液流動性改善
作用を有する医薬は、これを服用させることにより、ヒ
トに対して、血液の流動性改善作用を有しており、とり
わけ優れた白血球の流動性改善作用を有している。The medicament having a blood fluidity improving effect of the present invention according to claim 1 has a blood fluidity improving effect on humans when taken, and is particularly excellent. It has the effect of improving the fluidity of leukocytes.
【００３８】すなわち、請求項１記載の本発明の血液流
動性改善作用を有する医薬は、血液の流動性を著しく改
善させることができるため、微小血管、動脈硬化を起こ
している血管、血栓ができている血管などにおいて、赤
血球や白血球がスムーズに通過し、また、赤血球や白血
球が血管で壊れにくくなる。それ故、請求項１記載の本
発明の血液流動性改善作用を有する医薬は、ヒトの血液
流動性改善剤として、特に人工透析患者の血液流動性改
善剤として有用である。とりわけ白血球の流動性改善剤
として、人工透析患者や糖尿病患者、さらにはこれらの
予備軍的なものに対する予防薬として有用である。That is, the medicament of the present invention having a blood fluidity improving effect according to the present invention can remarkably improve blood fluidity, so that microvessels, blood vessels causing arteriosclerosis, and thrombus can be formed. In blood vessels and the like, red blood cells and white blood cells pass smoothly, and red blood cells and white blood cells are less likely to be broken by blood vessels. Therefore, the medicament having a blood fluidity improving effect of the present invention described in claim 1 is useful as a human blood fluidity improving agent, particularly as a blood fluidity improving agent for artificial dialysis patients. In particular, it is useful as a leukocyte fluidity improving agent, as a prophylactic agent for dialysis patients and diabetic patients, and also for these reserves.
【００３９】また、請求項２記載の本発明の血液流動性
改善作用を有する食品・飼料組成物は、これを摂取・服
用させることにより、ヒト及び動物に対して、血液の流
動性改善作用、とりわけ優れた白血球の流動性改善作用
を有している。Further, the food and feed composition having a blood fluidity improving effect of the present invention according to the second aspect of the present invention is capable of improving blood fluidity to humans and animals by ingesting and taking the composition. In particular, it has excellent leukocyte fluidity improving effect.
【００４０】すなわち、請求項２記載の本発明の血液流
動性改善作用を有する食品・飼料組成物は、血液の流動
性を著しく改善させることができるため、微小血管、動
脈硬化を起こしている血管、血栓ができている血管など
において、赤血球や白血球がスムーズに通過し、また、
赤血球や白血球が血管で壊れにくくなる。That is, the food / feed composition having a blood fluidity improving effect of the present invention according to the second aspect of the present invention can significantly improve the fluidity of blood, so that microvessels and blood vessels causing arteriosclerosis are obtained. Red blood cells and white blood cells pass smoothly in blood clots,
Red blood cells and white blood cells are less likely to be broken by blood vessels.
【００４１】また、請求項１記載の本発明の血液流動性
改善作用を有する医薬及び請求項２記載の本発明の血液
流動性改善作用を有する食品・飼料組成物は、安全性に
も優れたものであり、長期間投与（服用）、摂取しても
副作用がない。Further, the medicine having a blood fluidity improving effect of the present invention according to claim 1 and the food / feed composition having a blood fluidity improving effect of the present invention according to claim 2 have excellent safety. It has no side effects even if it is administered (taken) for a long time and ingested.
【００４２】従って、本発明は、動脈硬化の進展の防
止、血管が詰まることによる様々な障害，疾病の予防な
どの目的で、医療分野（請求項１記載の本発明の血液流
動性改善作用を有する医薬）や、食品分野，飼料分野
（特にペットフード分野）等（請求項２記載の本発明の
血液流動性改善作用を有する食品・飼料組成物）におい
て、有効に利用される。Therefore, the present invention is intended to prevent the progression of arteriosclerosis and to prevent various disorders and diseases caused by clogging of blood vessels, and to prevent the blood fluidity improving effect of the present invention according to the first aspect of the present invention. It is effectively used in the field of foods and feeds (particularly in the field of pet foods), etc. (the food and feed composition having the blood fluidity improving effect of the present invention according to claim 2).
【００４３】特に請求項１記載の本発明の血液流動性改
善作用を有する医薬は、血液の流動性、特に白血球の流
動性を改善することにより、白血球を安定化し、さらに
安定化されることによって炎症物質が出ないために、人
工透析患者のみならず、炎症性疾患を持つ人、動脈硬化
や癌の転移の予防・防止・改善に有効であると期待され
る。炎症性疾患の具体的な例としては、リウマチ、糖尿
病の合併症、痛風、慢性疼痛、アトピー性皮膚炎、腎
炎、肝炎等を挙げることができる。In particular, the medicament having a blood fluidity improving effect of the present invention according to the first aspect of the present invention stabilizes and further stabilizes leukocytes by improving blood fluidity, particularly leukocyte fluidity. The absence of inflammatory substances is expected to be effective not only for patients on dialysis but also for people with inflammatory diseases, prevention, prevention and improvement of arteriosclerosis and cancer metastasis. Specific examples of inflammatory diseases include rheumatism, complications of diabetes, gout, chronic pain, atopic dermatitis, nephritis, hepatitis and the like.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ａ６１Ｋ 45/00 Ａ６１Ｋ 45/00 (72)発明者 山田 恵子 大阪府大阪市住之江区御崎６丁目15番24号 402 (72)発明者 中島 寿昭 東京都港区芝五丁目６番１号 (72)発明者 近藤 彰宏 東京都港区芝五丁目６番１号──────────────────────────────────────────────────の Continued on front page (51) Int.Cl. 6 Identification code FI A61K 45/00 A61K 45/00 (72) Inventor Keiko Yamada 6-15-24 Misaki, Suminoe-ku, Osaka-shi, Osaka 402 402 (72) Inventor Toshiaki Nakajima 5-6-1 Shiba, Minato-ku, Tokyo (72) Inventor Akihiro Kondo 5-6-1 Shiba, Minato-ku, Tokyo
Claims (5)
と脂溶性抗酸化剤とを有効成分とする血液流動性改善作
用を有する医薬。1. A drug having an effect of improving blood fluidity, comprising γ-linolenic acid alone or γ-linolenic acid and a fat-soluble antioxidant as active ingredients.
γ−リノレン酸と脂溶性抗酸化剤とを有効成分とする血
液流動性改善剤。2. A blood fluidity improver comprising as an active ingredient the γ-linolenic acid alone or γ-linolenic acid and a fat-soluble antioxidant according to claim 1.
γ−リノレン酸と脂溶性抗酸化剤とを有効成分とする人
工透析患者の血液流動性改善剤。3. An agent for improving blood fluidity in an artificial dialysis patient, comprising as an active ingredient γ-linolenic acid alone or γ-linolenic acid and a fat-soluble antioxidant according to claim 1.
γ−リノレン酸と脂溶性抗酸化剤とを有効成分とする白
血球の流動性改善剤。4. A leukocyte fluidity improver comprising as an active ingredient the γ-linolenic acid alone or γ-linolenic acid and a fat-soluble antioxidant according to claim 1.
と脂溶性抗酸化剤とを含有することを特徴とする血液流
動性改善作用を有する食品・飼料組成物。5. A food / feed composition having an effect of improving blood fluidity, comprising γ-linolenic acid alone or γ-linolenic acid and a fat-soluble antioxidant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32216396A JP4473968B2 (en) | 1996-11-19 | 1996-11-19 | Blood cell fluidity improver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32216396A JP4473968B2 (en) | 1996-11-19 | 1996-11-19 | Blood cell fluidity improver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10147523A true JPH10147523A (en) | 1998-06-02 |
| JP4473968B2 JP4473968B2 (en) | 2010-06-02 |
Family
ID=18140646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32216396A Expired - Lifetime JP4473968B2 (en) | 1996-11-19 | 1996-11-19 | Blood cell fluidity improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4473968B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002114678A (en) * | 2000-10-06 | 2002-04-16 | Fuji Chem Ind Co Ltd | Agent for tocotrienol-containing medicine |
| US7678404B2 (en) | 2002-01-18 | 2010-03-16 | Kaneka Corporation | Ubiquinone-enriched foods |
-
1996
- 1996-11-19 JP JP32216396A patent/JP4473968B2/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002114678A (en) * | 2000-10-06 | 2002-04-16 | Fuji Chem Ind Co Ltd | Agent for tocotrienol-containing medicine |
| JP4693140B2 (en) * | 2000-10-06 | 2011-06-01 | 富士化学工業株式会社 | Tocotrienol-containing pharmaceutical agent |
| US7678404B2 (en) | 2002-01-18 | 2010-03-16 | Kaneka Corporation | Ubiquinone-enriched foods |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4473968B2 (en) | 2010-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001286576B2 (en) | Composition and method for treatment of hypertriglyceridemia | |
| DE69935995T3 (en) | POLYUNGATURATED FATTY ACIDS NUTRITIONAL SUPPLEMENT | |
| US6326031B1 (en) | Method of decreasing cholesterol and triglycerides levels with a composition containing fish oil, garlic, rutin, and capsaicin | |
| KR20030016306A (en) | Therapeutic combinations of fatty acids | |
| JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| JPH0369886B2 (en) | ||
| WO2015005443A1 (en) | Oral composition | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| CA2963952A1 (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| WO2008059965A1 (en) | Agent for alleviating or preventing stress symptoms and agent for improving mental conditions | |
| AU2008301694B2 (en) | Compositions Containing Sesamin-Class Compound(s) and Arachidonic Acid Class Compound(s) | |
| US20210322360A1 (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| US9808437B2 (en) | Monounsaturated fatty acid compositions and use for treating atherosclerosis | |
| JPWO2015163316A1 (en) | Composition for preventing or improving peripheral neuropathy | |
| JP2006213684A (en) | Composition and health food to be used for ameliorating insulin resistance | |
| CN108186631B (en) | Pharmaceutical composition and preparation method and application thereof | |
| JPH06199695A (en) | Agent for amelioration and treatment of diabetes | |
| US20220193018A1 (en) | Omega-3 compositions and methods relating thereto | |
| JP4473968B2 (en) | Blood cell fluidity improver | |
| US20160296492A1 (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| JP2000302677A (en) | Medicine and food/feed composition having improving action on carnitine self production ability | |
| CN106659707B (en) | Erythrocyte function-improving agent | |
| AU6282796A (en) | Fish oil and garlic nutritive composition | |
| JP3816545B2 (en) | Composition for treatment of cutaneous pruritus and composition for treatment of hyperparathyroidism in an artificial dialysis patient | |
| Shkolnikova et al. | Comparative Characteristics of Dosage Forms of α-Lipoic Acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050518 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050518 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070626 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070919 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071218 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080403 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080414 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080425 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080425 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100208 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100308 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130312 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20170312 Year of fee payment: 7 |
|
| EXPY | Cancellation because of completion of term |